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Introduction
Me ´decins Sans Frontie `res (MSF) is an
international humanitarian aid organisa-
tion that provides emergency medical
assistance to populations in danger in
more than 80 countries. In its work,
MSF is often confronted with situations
for which effective and feasible interven-
tions are lacking. As a result, over the past
few years, MSF has expanded its research
activities [1–4]. But although MSF often
works in close collaboration with scientific
institutes and ministries of health that have
their own ethical review mechanisms to
oversee research, MSF as a humanitarian
organisation has concerns that are distinct
from those of academic institutions and
wants to endorse with confidence any
research that takes place under its name
[5–7]. Furthermore, not all countries in
which MSF works have ethics committees,
some local ethics committees may not
have the resources to function optimally
[8–12], and the local or national govern-
ment is not always a guarantor for the
well-being of its population. For these
reasons, in 2001 MSF decided to institute
its own ethics review board (ERB).
Board Composition and Function
Currently, the ERB is composed of
seven members with an understanding of
humanitarian and non-governmental or-
ganisation realities. The mix of members
ensures good geographic (Africa, Asia,
Europe, North America) and professional
(medicine, public health, law, anthropolo-
gy, bioethics) variety [13,14]. To avoid
conflicts of interest and to ensure inde-
pendence, members cannot have a work-
ing relationship with MSF or be a member
of the board of an operational centre
during their tenures. Working procedures
are defined in the terms of reference of the
ERB [15]. Briefly, reviews are coordinated
by the chair, comments are provided
electronically by the board members, and
discussions on divergent views mainly
happen through e-mail exchange. After
the ERB makes its final decision, the
medical director of the MSF section
concerned is responsible for ensuring that
the research is implemented as approved
by the ERB; the ERB is not accountable
for any research carried out against its
advice. Every 18 months ERB members
meet in person with the MSF medical
directors to discuss ethical issues that were
problematic in their reviews and to make
general recommendations on how to
address those issues in future research.
The ERB recognises three types of
ethical review requirements:
N Full review, which requires the partic-
ipation of all the ERB members, is
warranted if a procedure or therapy of
unknown effectiveness or efficacy is
tested on people and/or if the research
involves collecting body/tissue samples
with hypothesis testing. Full review is
needed, therefore, for all clinical trials
and for some operational research
projects.
N Expedited review, which requires the
participation of two or three ERB
members, is deemed sufficient if the
research carries only minimal risks to
human participants. Research in this
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Summary Points
N In 2001, the international human-
itarian aid organisation Me ´decins
Sans Frontie `res decided to insti-
tute an independent ethics re-
view board to ensure that the
increasing amount of operational
and clinical research it undertakes
is scientifically valid and ethical.
N This article describes the func-
tioning of this ethics review board
and the challenging ethical issues
that it has discussed since its
inception.
The authors of this paper are the members of the Ethics Review Board instituted by Me ´decins Sans Frontie `res.
{Deceased.
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that involve monitoring and evaluation
to test a new approach, social science
research in health and health systems,
and prevalence and incidence studies.
N Review exemption applies to routine
programme implementation and as-
sessment-related work.
Approval of research by the ERB is time
limited—the study must start within one
year. Investigators must inform the ERB
about amendments to approved protocols,
about the results of interim analyses that
may lead to changes in protocol, and about
early stopping of a trial and/or abandon-
ment of a study. The ERB also asks to
receive the final results of the research either
as an internal report or as a published paper.
However, the ERB has no directoversight of
research implementation and is often unable
to judge whether the research results benefit
the study population. Furthermore, not all
research carried out by MSF is submitted to
the ERB for review.
A Framework for Ethics Review
During the first two years of its existence,
the ERB used a framework derived from
general guidelines on research ethics such
as the Declaration of Helsinki [16], the
Belmont report [17], and the Council for
International Organizations of Medical
Sciences guidelines [14] as a basis for
discussion when members’ opinions di-
verged. In 2003, in order to provide
structured advice to field researchers and
to facilitate standardised reviews, the ERB
decided to adapt a draft framework for
clinical research in the developing world
developed by the National Institutes of
Health in the United States [18]. This
framework was tested by the ERB for 18
months to assess its utility and feasibility
and, as a result, some of its benchmarks
were changed or expanded. Since March
2005, the revised version of the framework
has been used by the ERB (can be obtained
from MSF on demand) and, as hoped, has
standardised the review process and pro-
vided field research teams with valuable
guidance on how to address ethical issues.
Review Activity
Table 1 shows the workload of the ERB
since its inception. In 2006–2008, the
main themes of the protocols reviewed
were HIV/AIDS (16), tuberculosis (12),
and malaria (13). A further ten studies
were concerned with tropical diseases such
as leishmaniasis, cholera, Chagas disease,
Buruli ulcer, Marburg fever, and kala-
azar. The remaining protocols reviewed
over this period focused on mental health,
reproductive health, and nutrition.
As shown in Table 2, most studies
reviewed in 2006–2008 were designed to
either test a new intervention (diagnostic
test or clinical procedure) or to assess the
effectiveness of an intervention through a
prospective descriptive study (49/70 pro-
tocols reviewed). Only five clinical trials,
comparing the effectiveness of two or
more treatment schemes, were submitted.
On the other side of the research spec-
trum, a posteriori analysis of routinely
collected data represented almost a quar-
ter of the requested reviews.
Some Challenging Ethical Issues
Since its inception, the ERB has faced
several important ethical challenges. Some
of these challenges have been resolved
after extensive discussion at ERB meetings
but others remain unresolved.
Routine Data Monitoring
In MSF programmes, data are routinely
collected as part of clinical practice
Table 1. Number of protocols reviewed per year and status of research.
Number of Proposals/State of Research 2002 2003 2004 2005 2006 2007 2008
Number of proposals 5 8 6 3 14 34 23
Research articles published 2 6 2 1 4 8 0
Internal MSF reports produced 1 2 3 1 6 4 5
Research ongoing 0 0 0 0 2 19 18
Research cancelled/interrupted 2 0 1 1 2 3 0
Note: 11 proposals were submitted between January–March 2009.
doi:10.1371/journal.pmed.1000115.t001
Table 2. Type of research and approval process for studies submitted 2006–2008.












Direct approval 0 1 4 5 10
Approval after resubmission
a 41 4 2 0 3 4 1
No approval 1 (abandoned) 4 (2 abandoned; 1 without
approval, 1 pending)
2 (pending) 0 7
Advice before publication
b 00 4 8 1 2
Total 5 19 30 16 70
aIn most instances this means one cycle of resubmission; in a few cases, there were two cycles of resubmission.
bStudies that were not submitted to ethics review prior to implementation cannot be approved after the fact. However, the ERB has agreed to provide advice on ethical
issues prior to publication.
doi:10.1371/journal.pmed.1000115.t002
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are used a posteriori to test a research
hypothesis, ethics review should be sought
before doing the analysis, but as Table 2
shows, this has not always been the case.
In its discussions, the ERB agreed that in
most a posteriori studies, individual in-
formed consent is not feasible or not
deemed necessary. However, community
consent may be necessary if there is the
potential for harm to the community.
Other ethical issues related to routine data
monitoring that the ERB decided must be
considered are local partnerships, the
social value of the proposed research,
and the possible benefits for the commu-
nities involved. In addition, the ERB
decided that authorisation from the min-
istry of health concerned and/or a local
health institution should always be re-
quested before data are used retrospec-
tively to test a research hypothesis. Box 1
provides an example of how the ERB dealt
with a specific instance of retrospective
data analysis.
Emergency Research
In the past, MSF has often carried out
research in emergency situations without
first requesting ethics review. The ERB
has then been asked retrospectively to
review emergency research by providing
advice on draft papers before their publi-
cation. Because emergency research is
mostly carried out among highly vulnera-
ble populations, such research may have
serious implications for study participants
[19,20]. Consequently, the ERB and MSF
recently agreed that to facilitate research
in disaster situations, a ‘‘generic’’ research
protocol could be submitted for ERB
review and approval before the exact
location of the disaster is known. Once
the location is known, the details can be
filled in and subjected to expedited review
to allow the protocol to be applied in a
specific setting. MSF took this approach,
for example, when preparing a protocol
for research into meningitis treatment
before an expected outbreak actually
occurred. Importantly, even if the MSF
ERB grants ‘‘a priori’’ approval for
emergency research, the ERB has speci-
fied that approval from the national
authorities must always be sought before
the research project is implemented.
Qualitative Research
Investigations involving qualitative re-
search methods are sometimes not consid-
ered research by MSF (and hence not
submitted to ethics review), and the people
involved in these studies are seen as
‘‘informants’’ rather than ‘‘research partici-
pants’’ [21]. In its discussions, the ERB
decided, however, that ethical review might
sometimes be necessary in qualitative re-
search. For example, in one study of sexual
violence, information was collected from
affected women during in-depth interviews
[22]. This type of interview carries a risk of
psychologically harming people who have
had traumatic experiences. Ethical review
would help to assess the risk to individual
participants. It would also examine the
immediate value to the research community




As well as the challenge of defining who
or what constitutes a ‘‘community’’ [23],
particularly in the humanitarian context
where a community may be unstable and
transient, a question raised in almost every
proposal considered by the ERB is what
qualifies as community engagement? One
of the greatest ethical challenges facing the
ERB and MSF is to find ways in which
community participation can be ensured
and enhanced while being realistic about
time and resource constraints. This is a
particularly large challenge because per-
mission from state authorities and scien-
tists is sometimes confused with genuine
community engagement.
Ideally, a ‘‘functional’’ community body
(e.g., village committees, community advi-
sory boards) should be involved in each
research project. This can be an existing
body or one created for the specific
purpose of the project. At a minimum,
the community should be consulted during
the planning stage of the research, should
be consulted on an ad-hoc basis while the
research is being done, and should be
informed in a structured manner at the
end of the research about the results. The
ERB’s insistence on involving the commu-
nity early on in the research process has
led to more explicit deliberation on this
issue than previously (see Box 2 for a
specific example).
One particular ethical issue discussed by
the ERB that faces MSF is ensuring that
communities understand the difference
between receiving care and being involved
in research. A physician’s first goal is to
help the patient; a researcher’s first goal is
to find an answer to a research question.
As MSF does research in settings where
the organisation is already present in the
community and providing care, it can be
difficult for potential study participants to
understand the difference between receiv-
Box 1. Retrospective Analysis of Data from Patients with Kala-
Azar
Data were routinely collected during clinical practice in two settings in Africa and
analysed a posteriori to assess treatment effectiveness and risk factors for relapse
of kala-azar. The ERB approved this research because its social value is potentially
high. No individual or community consent for the data analysis was deemed
necessary in this context. However, local health authorities were informed and
agreed to the research. Importantly, MSF continues to work in these settings and
will be able to implement and advocate for a modification of treatment protocols
if applicable, and patients and communities will be informed about the outcomes
of the analysis.
Box 2. Community Involvement in a Comparative Trial
Examining the Efficacy and Safety of Three First-Line
Treatments for Visceral Leishmaniasis in Africa
The ERB found it difficult to judge from the initial proposal how collaboration
with local communities would be developed and how the community’s values,
culture, traditions, and social practices would be taken into consideration in
developing the research. The investigators replied: ‘‘MSF has been working in the
study community for over 7 years. We have a long tradition of close collaboration
with the local community in this project towards patient treatment. We have two
staff members—one a religious leader, the other a member of the local popular
committee—who have already been engaged and will continue in disseminating
information of the study to the local community. With these direct links as well as
through our other liaisons with the community (e.g.: health educators) we aim to
clearly explain the reasons and possible long-term benefits of the study to
community and religious leaders, village elders and the community at large. We
understand that building a collaborative partnership with the local community is
crucial for facilitating patient recruitment, treatment and follow up.’’
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Thus, it is important to engage the
community as early as possible in design-
ing the research, to have a dialogue
throughout the study, and to communicate
the results and implement change after the
research is complete. In addition, the
different ways of acting in regular pro-
grammes and in research must be clearly
laid out and, where relevant, different
contacts in the community (elders, leaders,
and district health officials) should be
established for operational purposes and
for research purposes. MSF should also be
careful not to ‘‘overuse’’ a community that
is well engaged by doing research in that
community on numerous occasions. Final-
ly, where MSF is the sole care provider, it
should be aware that the community may
not feel able to refuse or criticise research,
and must guard against that risk.
Informed Consent
Obtaining quality informed consent was
one of the major ethical challenges in most
of the research proposals reviewed by the
ERB. Examples of shortcomings include:
incomplete information given to the par-
ticipants about objectives, risks, adverse
effects, and planned house visits; informa-
tion too detailed and complicated; formu-
lation of the text biased to induce a
positive answer; overestimation of the
benefit for participants and community;
and lack of procedures to ensure that the
information provided is understood.
As well as suggesting ways to improve
the information provided, the ERB urges
researchers to put more emphasis on the
information exchange process between
researchers and potential participants
rather than on the formal consent form.
For example, potential research partici-
pants should be given the opportunity to
discuss their decision with their families,
and alternative ways to record consent if
individuals do not want to sign a consent
form but are willing to participate in the
proposed research should be sought. In
some settings where MSF operates, people
have declined to sign a consent form but
are prepared to sign a register. In other
settings, people have declined to sign
anything but have given oral consent. In
such circumstances, the ERB suggests that
the researcher can keep a written record
that the patient has been informed,
understood, and accepted to participate,
but declined to sign.
Collecting and Using Tissue Samples
The collection, export, and analysis of
tissues raises a host of ethical issues
concerning the potential commoditisation
and traffic of human identity and the
exploitation of communities from which
tissues have been taken [24–26]. Tissue
samples are a precious commodity and
extremely useful in the development of
new diagnostic tests for rare diseases such
as Ebola (see Box 3), Marburg fever, and
sleeping sickness.
One proposed solution to the ethical
issues associated with tissue sample collec-
tion and future use is to get prospective,
one-time approval from study participants
as part of the individual informed consent
procedure and then to get approval from
an ERB for any subsequent specific
research that uses these tissue samples
[27].
Since its inception, the MSF ERB has
sought to create a tissue policy consistent
with MSF’s humanitarian mandate to
remedy the current lack of guidance on
the management of samples in interna-
tional guidelines. Essential to this policy is
a commitment to serve the beneficiaries of
a humanitarian medical intervention, not
the interests of third parties such as the
developers of commercial tests. The ERB
recommends that if MSF engages in
research that involves the use of tissue
samples (including export and/or storage
for future use):
N Informed consent must be obtained,
whenever possible, from the research
participants on the intended use of the
samples (but see Box 4).
N The use of samples taken by MSF and
analysed in another laboratory should
Box 3. Tissue Samples Collected During an Ebola Outbreak
MSF has repeatedly been involved in treatment of patients and infectious control
during Ebola outbreaks. One major ethical issue that MSF has encountered during
these outbreaks is the fact that other organisations sometimes take tissue
samples from patients treated by MSF for further use without explicit consent.
Ideally, at the very minimum, the results of any investigations done on these
samples should be communicated to the patient and to the team in charge of
their clinical management. Unfortunately, there have been instances where
results have never been provided. In addition, it should also become standard
practice that the patient is informed about the fate of his/her tissue sample
(analysis and future use).
Box 4. The ERB’s Position on the Use of Tissue Samples without
Informed Consent
Investigators should be granted permission to use samples belonging to
deceased, lost to follow-up, withdrawn, and completed follow-up participants
only if:
1. The investigators omitted to obtain informed consent prospectively for the
samples in good faith (i.e., the investigators’ omission to obtain the informed
consent for future sample use was not willful or deliberate);
2. The investigators have made reasonable and good faith attempts to trace those
whose samples they seek to use (i.e., investigators must have made verifiable
attempts to locate the relevant participants and they must produce
documentation if requested that details the tracing process for each participant
whose samples they seek to use);
3. The investigators have engaged with the host community on the issue and have
received documented support from community representatives (such as a
community advisory board);
4. The use of samples in the manner requested is not against local laws (the onus
is on investigators to ascertain this and to notify the ERB accordingly);
5. There is a good scientific rationale for using such samples (the onus is on the
investigators to show why they cannot use prospectively collected samples for
their study);
6. The investigators/sponsor must clarify whether use/analysis of the samples
could result in intellectual property/commercial implications. If so, they must
outline a benefit-sharing plan or post-trial access plan with the local community.
Such plan(s) should result from prospective engagement with the host
community/community representatives and local authorities.
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of understanding (future use, destruc-
tion, etc.).
N When samples are stored, the labora-
tory storing the sample should provide
an annual report describing the fate
and use of samples.
N Before future use of anonymised indi-
vidual samples, community consent
should be sought.
These recommendations have led to a
much greater awareness on this issue in
MSF and are now being included in the
MSF research proposals sent to the ERB
for review.
Collaboration with For-Profit Entities
Sometimes MSF carries out operational
research to field-test new technological
devices. The results of this research could
potentially benefit for-profit entities. A
major ethical issue, therefore, is whether
the benefits of the research will be shared
with the study participants and communi-
ty, either through profit sharing or
through a guarantee of preferential access.
Both these benefit-sharing approaches
need to be negotiated before the research
starts. In most instances preferential access
is the easier and better option.
If MSF carries out research with a for-
profit entity or research that could directly
benefit a for-profit entity, the ERB has
suggested the following guidelines:
N Informed consent must be obtained
and must ensure that the research
participant is fully informed about the
potential commercial benefits of the
research.
N Preferential access should be guaran-
teed through a contractual agreement
between the company and the govern-
ment of the country where the re-
search takes place; if useful, this
agreement should also involve MSF.
N Ethical considerations related to ben-
efit sharing must be given due atten-
tion before the research starts and
should include discussions with the
communities involved.
As illustrated in Box 5, these recom-
mendations have had some impact in the
field. However, the development of a
consistent MSF policy that includes these
recommendations remains a challenge.
Making Research Benefits Available
MSF usually carries out research with
the intention of delivering the results of the
study to the community involved in the
research. However, MSF may sometimes
want to test an intervention that is too
expensive at the outset of the research to
be made immediately available to every-
one who needs it. In view of the ERB,
MSF can start such research if there are
good reasons to expect a considerable
price drop and if MSF initiates advocacy
and lobbying efforts at the same time. This
was the situation with the randomised
controlled trials of artemisinin combina-
tion therapy for malaria that were largely
undertaken in Africa and Asia and where
price drops have since been achieved and
easier-to-use formulations have become
available. Box 6 illustrates how uncertain-
ty about the affordability of an interven-
tion can remain at the time of approval.
A further issue is the commitment of
MSF to make the intervention tested in the
research available to the community
[14,28] for a certain time period. In view
of the ERB, ‘‘reasonable availability’’ of an
intervention tested means that MSF should
commit to stay for a minimum of two years
after the end of the research. If the
organisation leaves, the intervention should
be made available to the local population
through other means (e.g., other interna-
tional organisation or the country’s minis-
try of health). However, the fact that MSF
may leave earlier than anticipated due to
organisational or political reasons and may
not be able to engage local authorities in
the provision of research benefits remains
an ethical concern.
Conclusions
The ERB instituted by MSF has been in
p l a c ef o rs e v e ny e a r s ,a n dt h en e e df o r
Box 5. Testing the Effectiveness of a New Tuberculosis Detection
Device
A study had been designed to use sputum samples taken during routine clinical
assessment from patients at high risk of multidrug-resistant tuberculosis to
compare conventional culture methods with a new, more rapid tuberculosis
culture and drug susceptibility device. The social value of the study was
potentially high and the risk to research participants minimal. However, the
results of the research could lead to commercial benefits. The investigators were
not intending to seek informed consent and did not intend to inform the patient
about the use of their samples in this study. The ERB pointed out that: ‘‘Sharing
fairly the financial and other rewards of the research is a major ethical issue. This
study uses an area of high tuberculosis burden to get the data needed to perfect
a technology with commercial potential. The patients are unaware that their
illness will eventually increase the profit of the corporation that produces the
technology…There is a risk of fostering dependence on a superior technology
without assuring affordability past a very narrow time horizon. MSF should thus
insist on much stronger long term affordability. We would like to be assured of
MSF’s commitment to do so.’’ Consequently, a consent procedure was developed
that explicitly informed patients about the further use of their sputum samples,
about the partners involved in the research, and about potential commercial
benefits. MSF also made a commitment to more proactive advocacy regarding
access to the new test in the future.
Box 6. Testing a Nutritional Intervention That May Not Be
Sustainable
A proposed study of the effectiveness of a patented ready-to-use therapeutic
food (RUTF) in catch-up growth of children after an acute episode of malaria in a
hyperendemic area in Africa was considered by the ERB. The usefulness of
providing supplementary food to children in convalescence was not questioned
by the ERB. However, this RUTF is expensive and would have to be delivered on a
broad scale in a severely resource-constrained environment. The ERB thus
questioned the appropriateness of the research. MSF argued that an initial pilot
study was necessary to assess the benefits of providing RUTF in convalescence
since it could not ask for government commitment to the intervention without
evidence that it works effectively. On a different level, MSF is currently
campaigning to change international recommendations on early treatment and
prevention strategies in malnutrition and is also working on price reductions of
this specific RUTF as well as increasing the supply, possibly through local
production, of other RUTFs.
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in addition to local ethics approval is now
well accepted within the organisation. The
MSF ERB often has a different perspective
from that of academic institutions. In
particular, it is more oriented towards
programmatic relevance (feasibility issues)
and is sensitive to vulnerable populations
and equity issues.
The number and quality of research
proposals reviewed by the ERB has
increased considerably year on year. As
well as scrutinising the ethical soundness of
MSF research protocols, the ERB has also
played an important role in launching an
on-going debate on research ethics issues
within MSF. The ERB recommendations
have sensitised MSF researchers to ethical
issues that they may have overlooked
previously and have consequently changed
practice. However, it will take more time
to translate these recommendations into
organisational policy.
International humanitarian organisa-
tions such as MSF will be faced with even
more complex health problems in the
future as the global environment changes.
Research to devise and test new interven-
tions will remain an important part of
MSF’s agenda, and will most probably
increase. As this happens, a major concern
will be to ensure that communities in
which such research takes place are
empowered to become true partners and
that vulnerable individuals and groups are
effectively protected [29]. The ethical
oversight provided by the MSF ERB will
be crucial in addressing these challenges.
Acknowledgments
The ERB members would like to thank the
international medical director of MSF and past
and current medical directors of the operational
centres for entrusting us with the challenging
task of overseeing the ethics review of MSF
research. Their openness and willingness to
improve research practice within MSF has led
to many stimulating and fruitful discussions.
The content of the paper has been shaped by
the reviews conducted and the discussions
among ERB members and with MSF research-
ers.
Author Contributions
ICMJE criteria for authorship read and met:
DS RU FM JAS SB AA EvD. Wrote the first
draft of the paper: DS. Contributed to the
writing of the paper: RU FM JAS SB AA EvD.
References
1. Delisle H, Hatcher Roberts J, Munro M, Jones L,
et al. (2005) The role of NGOs in global health
research for development. Health Res Policy Syst
3: 1–21.
2. Pecoul B, Chirac P, Trouiller P, Pinel J (1999)
Access to essential drugs in poor countries. A lost
battle? JAMA 281: 361–367.
3. Trouiller P, Olliaro P, Torreele E, Orbinski J,
Laing R, et al. (2008) Drug development for
neglected diseases: A deficient market and a
public-health failure. Lancet 359: 2188–2194.
4. Brown V, Guerin PJ, Legros D, Paquet C,
Pe ´coul B, et al. (2008) Research in complex
humanitarian emergencies: The Me ´decins Sans
Frontie `res/Epicentre experience. PLoS Med 5:
e89. doi:10.1371/journal.pmed.0050089.
5. Gilman RH, Garcia HH (2008) Ethics review
procedures for research in developing countries:
A basic presumption of guilt. CMAJ 171:
248–249.
6. Nuffield Council on Bioethics (2002) The ethics of
research related to health care in developing
countries. Available: http://www.nuffieldbioethics.
org/go/ourwork/developingcountries/publication_
309.html. Accessed 19 June 2009.
7. Dieudonne ´ DA (2007) Research ethics and
developing countries. J Int Bioe ´thique 18: 69–73.
8. Elsayed DE, Kass NE (2007) Assessment of
ethical review process in Sudan. Dev World
Bioeth 7: 143–148.
9. Hyder AA, Wali SA, Khan AN, Teoh NB,
Kass NE, et al. (2004) Ethical review of health
research: A perspective from developing country
researchers. J Med Ethics 30: 68–72.
10. Ikingura JK, Kruger M, Zeleke W (2007) Health
research ethics review and needs of institutional
ethics committees in Tanzania. Tanzan Health
Resr Bull 9: 154–158.
11. Kass NE, Hyder AA, Ajuwon A, Appiah-Poku J,
Barsdorf N, et al. (2007) The structure and
function of research ethics committees in Africa:
A case study. PLoS Med 4: e3. doi:10.1371/
journal.pmed.0040003.
12. Abdur Rab M, Afzal M, Abou-Zeid A,
Silverman H (2008) Ethical practices for health
research in the Eastern Mediterranean region of
the World Health Organization: A retrospective
data analysis. PLoS ONE 3: e2094. doi:10.1371/
journal.pone.0002094.
13. Canadian Institutes of Health Research, Natural
Sciences and Engineering Research Council of
Canada, Social Sciences and Humanities Research
Council of Canada (2008) Tri-council policy
statement: Ethical conduct for research involving
humans. Available: http://pre.ethics.gc.ca/eng/
policy-politique/tcps-eptc/readtcps-lireeptc/. Ac-
cessed 19 June 2009.
14. Council for International Organizations of Med-
ical Sciences (2002) International ethical guide-
lines for biomedical research involving human
subjects. Available: http://www.cioms.ch/frame_
guidelines_nov_2002.htm. Accessed 19 June
2009.
15. Me ´decins Sans Frontie `res (2009) MSF field re-
search: MSF ethics. Available: http://fieldresearch.
msf.org/msf/handle/10144/11645. Accessed 22
June 2009.
16. World Medical Association (2008) World Medical
Association Declaration of Helsinki: Ethical
principles for medical research involving human
subjects. Available: http://www.wma.net/e/policy/
b3.htm. Accessed 22 June 2009.
17. The (US) National Commission for the Protection
of Human Subjects of Biomedical and Behavioral
Research (1979) The Belmont Report. Ethical
principles and guidelines for the protection of
human subjects of research. Department of
Health, Education, and Welfare. National Insti-
tutes of Health. Available: http://ohsr.od.nih.
gov/guidelines/belmont.html. Accessed 22 June
2009.
18. Emanuel EJ, Wendler D, Killen J, Grady C
(2004) What makes clinical research in developing
countries ethical? The benchmarks of ethical
research. JID 189: 930–937.
19. Leaning J (2001) Ethics of research in refugee
populations. Lancet 357: 1432–1433.
20. Black R (2003) Ethical codes in humanitarian
emergencies: From practice to research. Disasters
27: 95–108.
21. Haggarty KD (2004) Ethics creep: Governing
social science research in the name of ethics. Qual
Sociol 27: 391.
22. Watts C, Heise L, Ellsberg M, Garcia-Moreno C
(2001) Putting women first: Ethical and safety
recommendations for research on domestic vio-




23. Tindana PO, Singh JA, Tracy CS, Upshur REG,
Daar AS, et al. (2007) Grand challenges in global
Health: Community Engagement In Research In
Developing Countries. PLoS Med 4: e273.
doi:10.1371/journal.pmed.0040273.
24. Upshur REG, Lavery JV, Tindana PO (2007)
Taking tissue seriously means taking communities
seriously. BMC Med Ethics 8: 1–6.
25. Andanda PA (2008) Human-tissue-related inven-
tions: Ownership and intellectual property rights
in international collaborative research in devel-
oping countries. J Med Ethics 34: 171–179.
26. Langat SK (2005) Reuse of samples: Ethical issues
encountered by two institutional ethics review
committees in Kenya. Bioethics 19: 537–549.
27. Wendler D (2006) One-time general consent for
research on biological samples. BMJ 332:
544–547.
28. Pace C, Grady C, Wendler D, Bebchuk JD,
Tavel JA, et al. (2006) Post-trial access to tested
interventions: The views of IRB/REC chair,
investigators, and research participants in a
multinational HIV/AIDS study. AIDS Res
Hum Retroviruses 22: 837–841.
29. Zwi AB, Grove NJ, Mackenzie C, Pittaway E,
Zion D, et al. (2006) Placing ethics in the centre:
Negotiating new spaces for ethical research in
conflict situations. Global Public Health 1:
264–277.
PLoS Medicine | www.plosmedicine.org 6 July 2009 | Volume 6 | Issue 7 | e1000115